drugset / Trial / NCT01225913

Mechanism(s) of Airflow Limitation During Exacerbation of Asthma

NCT01225913

Phase 4 Recruiting 50 enrolled Gelb, Arthur F., M.D.
NaSingle-groupOpen-labelBasic science

Summary

The purpose of this study is to evaluate the site and mechanisms responsible for expiratory airflow limitation in chronic, treated, non-smoking, stable asthmatics with moderate to severe persistent expiratory airflow obstruction. Treatment will include inhaled corticosteroids and long acting beta2agonists. The investigators are interested in determining whether the large and/or small airways are the predominant site of airflow limitation. The investigators are also interested in determining whether intrinsic small airways obstruction and/or loss of lung elastic recoil is responsible for expiratory airflow limitation. The investigators are also interested to evaluate the role of varying doses of inhaled corticosteroids to suppress large and small airway inflammation using exhaled nitric oxide as surrogate markers of inflammation. For comparison purposes, spirometry and measurements of exhaled nitric oxide will also be obtained if possible during a naturally occurring exacerbation of asthma.

Timeline

Start
2007-10
Primary completion
2027-06
Completion
2027-06

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Budesonide Small molecule 80 ug Inhaled
Subject Budesonide Small molecule 160 ug Inhaled
Subject Fluticasone Other / unclassified 100 ug Inhaled
Subject Fluticasone Other / unclassified 250 ug Inhaled
Background Formoterol Other / unclassified 4.5 ug Inhaled
Background Salmeterol Other / unclassified 50 ug Inhaled

Indications